•  

The Hospital for Sick Children (SickKids)

Phenotips Raises $2.5M in First Round of Financing

Our startup company, Phenotips (formerly Gene42), announced in September, 2021, that it raised C$2.5M in its first round of financing. TIAP was an early investor and most recently, in this round, participated with additional $100K through its FedDev program. This brings TIAP's total investment as of September 2021 to $300K. Read more about the financing round here. Phenotips has developed the world’s first "Genomic Health Record,” which offers software to standardize and share genomic medicine workflows. It is now translated into 5 ... Read more

TIAP & Amgen Co-funds transformative projects to support new venture development

December 8, 2020 TIAP announces co-funding of transformative projects with Amgen to support new venture development Toronto Innovation Acceleration Partners (TIAP) is excited to announce co-investments made with a key strategic partner, Amgen Inc., into three translational life sciences projects from its members: University of Toronto, University Health Network (UHN) and The Hospital for Sick Children (SickKids). The TIAP-Amgen partnership, formalized in 2019, has an objective to jointly fund nascent technologies managed by TIAP on behalf of its Toronto-based member institutions. The two organizations ... Read more

LAB150 adds two projects: Cystic Fibrosis and Respiratory Syncytial Virus

Toronto, ON, Feb. 27, 2019 (GLOBE NEWSWIRE) -- MaRS Innovation announced today the concurrent launch of two new LAB150 projects. These projects build on breakthroughs in disease-focused scientific research by prominent teams at The Hospital for Sick Children (SickKids) and the University of Toronto, both of which are Members of MaRS Innovation. LAB150 is a partnership between MaRS Innovation and Evotec AG with the goal of accelerating academic research towards commercial outcomes by providing funding and access to pharmaceutically validated platforms ... Read more

MaRS Innovation and KHIDI commence joint research initiatives

TORONTO, ON--(Marketwired - April 18, 2017) - MaRS Innovation (MI) and its South Korean partner, Korea Health Industry Development Institute (KHIDI), continue to build on the five-year global partnership agreement signed in December 2016 during Premier Wynne's mission to the Republic of Korea. Together with Minister Moridi, Ontario Minister of Research, Innovation and Science, Rafi Hofstein, CEO of MI, is in Seoul to further the joint research initiatives first envisaged last year. Five outstanding Ontario scientists from some of MI's Member institutions are ... Read more

ScarX announces approval for trial of first clinically-promising scar reduction cream

Toronto, August 18, 2016 – Toronto-based ScarX Therapeutics (ScarX) has received approval from Health Canada to begin a Phase I clinical trial of its SCX-001 nefopam cream, a first-of-its-kind topical treatment developed to significantly reduce surgical scarring. This announcement was covered in Yahoo Finance, The Canadian Business Journal, Global News Wire, and BioSpace. Applied immediately after surgical wound closure, SCX-001 reduces the amount of scar tissue that develops during the body’s natural healing process. The 24-subject Phase I clinical trial will be conducted at ... Read more

Johnson & Johnson Innovation Opens JLABS @ Toronto

TORONTO (May 11, 2016) –  Johnson & Johnson Innovation LLC, today announced the opening of JLABS @ Toronto, a new 40,000-square-foot life sciences incubator, providing entrepreneurs shared lab space and offices, modular lab suites and access to scientific, industry and capital funding experts as they work to build important and successful early-stage companies. The new JLABS facility can accommodate up to 50 start-ups and opens with 22 companies that represent a range of sectors including therapeutics, medical devices and consumer health ... Read more

ScarX Therapeutics closes $2 million Series A financing

Canadian biotech company developing ground-breaking therapeutic designed to minimize dermal scarring (fibrosis)   TORONTO (February 16, 2016) — ScarX Therapeutics, a Canadian biotechnology company commercializing innovative treatments for dermal scarring (fibrosis), has closed a $2 million Series A financing. The company will complete a Phase I clinical trial of its lead candidate, SCX-001, in human volunteers, with the eventual goal of creating better functional and cosmetic patient outcomes. This announcement was covered in TechVibes, BetaKit, Biotechnology Focus, PEHub, Finsmes, and StartupHere Toronto. SCX-001 is the ... Read more

Ontario advancing nine medical research projects in cancer, heart disease and sleep apnea to market

Applications for next MSc PoP granting round being accepted until February 25, 2016 TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children. Applications for the next MSc PoP granting round are open until March 4, 2016. To ... Read more

Ontario Government, University of Toronto, and MaRS secure Johnson & Johnson Innovation, JLABS for Toronto – first JLABS Incubator outside of United States

Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI's 15 member institutions   TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto. This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic ... Read more

MaRS Innovation featured in International Innovation magazine

MaRS Innovation and its member institutions are is profiled in International Innovation's July issue (#191) in a feature interview with Dr. Rafi Hofstein, MI's president and CEO, written by Rosemary Peters. The article is posted on the publication's website and viewable through a digital interface (pages 80 and 81). Here's an excerpt from Dr. Hofstein's comments: "Canada's academic research community is internationally highly competitive, but it has been argued that its scientific commercial success tags behind other countries such as the U.S. and the ... Read more
Page 1 of 41234